Vaxart Earnings Reports

Vaxart reported its Q3 2024 financial results, highlighting the ongoing progress with the COVID-19 vaccine program, including the near completion of enrollment for the sentinel cohort in the Phase 2b study. The company also received feedback from the FDA on its norovirus program and is evaluating next steps.

Vaxart reported its Q2 2024 financial results, securing a significant BARDA contract of up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine. The company also reported positive Phase 1 data for its bivalent norovirus vaccine candidate and extended its cash runway.

Vaxart announced positive topline results from its Phase 1 trial of an oral pill bivalent norovirus candidate focused on lactating mothers. They also anticipate initiating a Phase 2b study evaluating their XBB COVID-19 vaccine candidate as early as the second quarter of 2024.

Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022. Revenue for the full year 2023 was $7.4 million, compared to $0.1 million for 2022. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.

Vaxart announced its Q3 2023 financial results, highlighting topline data from Phase 2 trials of its norovirus program. The company's monovalent norovirus candidate showed potential in reducing norovirus infection, acute gastroenteritis, and viral shedding. Vaxart ended the quarter with $53.0 million in cash, cash equivalents, restricted cash and marketable securities, anticipating cash runway into Q3 2024.

Vaxart reported a revenue of $1.4 million and a net loss of $22.6 million for the second quarter of 2023. The company's cash runway has been extended into Q3 2024.